Gregg Fonarow is a Cardiology physician affiliated with University of California, Los Angeles. OpenAlex indexes 2,989 publications with 199,593 citations (h-index 198); ClinicalTrials.gov lists 1 registered study matched to this name. By OpenAlex citation count, this profile ranks in the top 1% of Cardiovascular Disease profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
200 Medical Plaza
#214,365,530,420,120
Los Angeles, CA 900953075
Telephone
310-825-8811Registry record last updated 14 Jun 2010.
Clinical trials
- IMPROVE HF: Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting
Sponsor: Medtronic Cardiac Rhythm and Heart Failure
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
16 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Alnylam Pharmaceuticals Inc.Program year20251 payment
- Bayer Healthcare Pharmaceuticals Inc.Program year20251 payment
- PFIZER INC.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
78.2%Beta blocker18.9%Carvedilol100%Part D≥27 patientsStatin15.5%Atorvastatin Calcium80%Simvastatin20%Part D<11 patients+ 7 more classes in this area
Metabolism & gastrointestinal
16%SGLT2 inhibitor13.3%Farxiga100%Part D≥14 patientsPotassium supplement2.7%Potassium Chloride100%Part D<11 patientsBlood & clotting
5.8%Factor Xa inhibitor5.8%Eliquis100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2002–2006 per NIH RePORTER. The latest:
- ACTION - A CHF Trial Investigating Outcomes of Exercise
University of California Los Angeles
FY2006$15,506U01HL068980 - ACTION - A CHF Trial Investigating Outcomes of Exercise
University of California Los Angeles
FY2005$129,116U01HL068980 - ACTION - A CHF Trial Investigating Outcomes of Exercise
University of California Los Angeles
FY2004$76,507U01HL068980
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Heart Failure Epidemiology and Outcomes Statistics: A Report of the Heart Failure Society of America
Journal of Cardiac Failure
2023 - 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Journal of the American College of Cardiology
2022 - 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary
Journal of the American College of Cardiology
2022 - Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure
European Journal of Heart Failure
2021 - 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction
Journal of the American College of Cardiology
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Dennis Slamon, MD
University of California, Los Angeles
Tomas Ganz, MD
University of California, Los Angeles
Richard Casaburi, MD
University of California, Los Angeles
Timothy Cloughesy, MD
University of California, Los Angeles
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”